TB-500 + GHK-Cu Stack: Complete Protocol, Dosing, and Evidence Review

What Are TB-500 and GHK-Cu?

TB-500 is a synthetic version of the actin-sequestering peptide thymosin beta-4 (Tβ4), specifically the tetrapeptide fragment Ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline). GHK-Cu is a tripeptide, glycine-histidine-lysine, that binds copper (II) ions. Both occur naturally in human plasma and tissue fluids, yet each operates through a different molecular entry point.

TB-500: Mechanism of Action

TB-500 promotes cell migration by binding G-actin and preventing actin polymerization. This shifts cells into a motile phenotype that accelerates wound closure and blood vessel formation. A 2010 paper by Goldstein and Kleinman in Annals of the New York Academy of Sciences described how the Ac-SDKP fragment retains the wound-healing activity of the full Tβ4 molecule [1]. Animal data from cardiac injury models show that Tβ4 reduces scar collagen deposition by roughly 30 to 40% relative to controls and improves left ventricular ejection fraction after myocardial infarction [2].

Tβ4 also downregulates NF-κB signaling. That pathway governs the transcription of TNF-α, IL-1β, and IL-6, so suppressing it reduces the acute inflammatory burden in injured tissue [3].

GHK-Cu: Mechanism of Action

GHK-Cu works differently. The tripeptide binds Cu²⁺ and delivers it to lysyl oxidase, the enzyme that cross-links collagen and elastin fibers. This process tightens extracellular matrix architecture and increases tissue tensile strength. Pickart and Margolina, writing in Scientific Reports (2018), documented that GHK activates over 4,000 human genes, with a strong bias toward tissue remodeling and antioxidant defense [4].

GHK-Cu also stimulates TGF-β1 production. TGF-β1 drives fibroblast proliferation and collagen type I synthesis, which is the structural collagen that gives healed tissue its mechanical properties [5].

Why Stack These Two Peptides?

TB-500 and GHK-Cu do not simply duplicate each other. They intervene at different points in the same repair cascade, which is the rationale for combining them.

Complementary Pathway Coverage

TB-500 accelerates cell migration and reduces acute inflammation. GHK-Cu then promotes the structural consolidation phase: cross-linking new collagen, restoring antioxidant defenses, and signaling fibroblast maturation. In a simplified repair timeline, TB-500 handles the first 48 to 96 hours of an injury response while GHK-Cu does more work in the remodeling phase that follows over weeks.

Animal data support this sequencing. A 2012 rodent tendon-injury study found that Tβ4 treatment significantly increased collagen III deposition at 2 weeks, which is the provisional scaffold [6]. GHK-Cu treatment in separate animal wound models increased collagen I deposition at 4 weeks, the mature structural layer [7]. Combining both theoretically covers both phases.

Anti-Inflammatory Combination Without Redundancy

Neither peptide suppresses inflammation through the same receptor. TB-500 acts through actin-mediated NF-κB inhibition; GHK-Cu reduces oxidative stress by upregulating superoxide dismutase and catalase expression [4]. A practitioner stacking both gets two distinct anti-inflammatory mechanisms running in parallel, without receptor competition or feedback redundancy.

The HealthRX clinical framework for this stack divides the repair process into three windows. Window 1 (days 0 to 7): TB-500 drives cell migration and curbs acute inflammation. Window 2 (days 7 to 28): GHK-Cu accelerates collagen cross-linking while TB-500 maintains its angiogenic effect. Window 3 (weeks 4 to 8): both peptides taper together as remodeling consolidates. This framework is not validated by an RCT but aligns with the mechanistic timing data available in peer-reviewed literature.

Evidence Quality: What the Data Actually Show

This is a critical section. Practitioners and patients need an honest accounting of what is known versus assumed.

Human Data on TB-500

No published RCT has tested TB-500 (Ac-SDKP fragment) in healthy human athletes or patients with musculoskeletal injury. The human data on the parent molecule, thymosin beta-4, come from a Phase II trial (NCT01311518) examining Tβ4 in patients with dry eye syndrome [8]. That trial showed modest corneal staining improvement but was not powered for systemic recovery endpoints. Cardiac applications of Tβ4 have been studied in rodent and porcine infarct models, showing meaningful functional recovery, but a human cardiac trial has not reached completion with published results.

Practitioner-reported outcomes in sports medicine settings describe 2 to 5 mg injections producing noticeable reduction in tendon and ligament pain within 2 to 3 weeks, but these are anecdotal reports without controls.

Human Data on GHK-Cu

GHK-Cu has a longer human evidence trail, mostly in dermatology. Double-blind trials in humans have shown that topical GHK-Cu at 0.1 to 1% concentration increases skin thickness by approximately 23%, reduces fine lines, and accelerates wound closure after dermabrasion [9]. Systemic injectable GHK-Cu data in humans are sparse, though plasma GHK levels have been characterized across age groups, declining from roughly 200 ng/mL at age 20 to under 80 ng/mL by age 60 [10].

Animal and In Vitro Data for the Combination

No published study has tested the TB-500 and GHK-Cu combination simultaneously in a controlled animal model. Researchers have studied each peptide separately in overlapping injury models. Because the pathway targets are distinct, additive benefit is biologically plausible, but plausibility is not proof.

Practitioners and patients should treat this stack as an experimental protocol with promising mechanistic rationale and a favorable short-term safety signal from each peptide independently.

Complete Dosing Protocol

The following protocol is synthesized from published mechanistic data, available animal evidence, and practitioner experience. It has not been validated in an RCT. All use of these peptides in humans outside an approved clinical trial is off-label or research-use classification.

TB-500 Dosing

Loading phase (weeks 1 to 4): 2 to 5 mg per injection, subcutaneous or intramuscular, twice per week. Many practitioners start at 2 mg per injection to assess tolerance before moving to 5 mg. Total weekly dose during loading: 4 to 10 mg.

Maintenance phase (weeks 5 to 8): 2 to 2.5 mg per injection, once per week. This mirrors the dosing pattern reported in the cardiac Tβ4 animal literature, which used front-loaded protocols [2].

Reconstitution: Bacteriostatic water is standard. A 5 mg vial reconstituted with 1 mL bacteriostatic water yields 5 mg/mL. A 0.4 mL draw delivers 2 mg.

Injection site: Subcutaneous abdomen or lateral thigh. Rotating sites reduces local tissue reactions.

GHK-Cu Dosing

Loading phase (weeks 1 to 4): 1 to 2 mg subcutaneous per injection, 3 to 5 times per week. The higher frequency reflects GHK-Cu's shorter plasma half-life relative to TB-500. Some practitioners use 1 mg daily during the loading phase.

Maintenance phase (weeks 5 to 8): 1 mg per injection, 2 to 3 times per week.

Reconstitution: Same bacteriostatic water protocol. A 50 mg vial with 25 mL bacteriostatic water yields 2 mg/mL. A 0.5 mL draw delivers 1 mg.

Topical co-use: Several practitioners also apply a topical GHK-Cu serum (0.1 to 1%) to the injury site daily during the cycle. This adds a local depot effect without substantially increasing systemic copper load.

Combined Weekly Schedule (Loading Phase Example)

| Day | TB-500 | GHK-Cu | |-----|--------|--------| | Monday | 2 to 5 mg SC/IM | 1 to 2 mg SC | | Tuesday |, | 1 to 2 mg SC | | Wednesday |, | 1 to 2 mg SC | | Thursday | 2 to 5 mg SC/IM | 1 to 2 mg SC | | Friday |, | 1 to 2 mg SC | | Saturday |, |, | | Sunday |, |, |

Cycle Structure and Off-Cycle Recommendations

A standard cycle runs 8 weeks total: 4 weeks of loading followed by 4 weeks of maintenance. After completing the 8-week cycle, practitioners generally recommend a minimum 4-week off period before repeating.

Why the Off Period Matters

Continuous peptide use raises two concerns. First, receptor desensitization or downregulation of downstream signaling is possible with sustained peptide exposure, though direct evidence for this with TB-500 or GHK-Cu in humans is lacking. Second, copper accumulates in tissues with prolonged GHK-Cu use. Copper toxicity is rare at therapeutic doses, but a serum ceruloplasmin and copper panel before and after each cycle is a reasonable precaution [11].

Injury-Specific Cycle Adjustments

For acute soft-tissue injuries (tendon tears, ligament sprains), beginning the stack within 48 to 72 hours of injury and running a full 8-week cycle aligns with the tissue remodeling timeline. For chronic tendinopathy, a shorter 4 to 6 week loading phase may be sufficient before dropping to maintenance or cycling off.

Safety Profile and Side Effects

Each peptide has been studied independently. No combined safety data exist.

TB-500 Side Effects

Side effects reported with TB-500 in practitioner case series include mild fatigue, lightheadedness, and transient flu-like symptoms in the first 24 to 48 hours after the first injection. These are generally self-limiting. One theoretical concern raised in oncology literature is that Tβ4 promotes angiogenesis, which could theoretically support tumor vascularization. The American Cancer Society has not published a position specifically on Tβ4 fragments, but any individual with a history of malignancy should consult an oncologist before use [12].

GHK-Cu Side Effects

GHK-Cu is well tolerated topically. Systemic injectable use carries a small risk of injection site reactions, hyperpigmentation at injection sites (due to local copper-melanin interactions), and, theoretically, copper overload with excessive or prolonged dosing. Standard therapeutic doses of 1 to 2 mg per injection are well below the doses associated with copper toxicity in animal models [11].

Contraindications

Neither peptide should be used during pregnancy or breastfeeding. Use is not appropriate for individuals with Wilson's disease (copper metabolism disorder) for GHK-Cu. TB-500 is not appropriate for individuals with active cancer or a history of certain hormone-sensitive cancers, given its angiogenic activity.

Who May Benefit From This Stack

Based on mechanism and practitioner experience, the individuals most likely to see benefit from this combination include those recovering from:

• Partial tendon or ligament tears (rotator cuff, Achilles, patellar tendon)
• Muscle belly injuries with significant scar tissue formation
• Post-surgical soft-tissue healing (orthopedic or reconstructive)
• Skin remodeling goals (scar revision, age-related matrix decline)

The peptide stack is not a substitute for physical therapy, surgical repair of complete tears, or other evidence-based interventions. Physical rehabilitation should run concurrently.

A Note on Athletes and Drug Testing

The World Anti-Doping Agency (WADA) prohibits thymosin beta-4 and its fragments under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) of the WADA Prohibited List [13]. Any competitive athlete subject to anti-doping testing should not use this stack.

Sourcing, Compounding, and Legal Status

In the United States, TB-500 and GHK-Cu are not FDA-approved drugs for human use. They are available from research chemical suppliers and, historically, from compounding pharmacies under FDA enforcement discretion. The FDA's 2023 guidance on bulk drug substances tightened restrictions on several peptides available through 503A and 503B compounding pharmacies [14]. Patients should verify the current compounding status with a licensed compounding pharmacy and work with a physician familiar with this regulatory field.

Purity and sterility vary widely between suppliers. A certificate of analysis (CoA) from an independent third-party laboratory showing greater than 98% purity by HPLC is the minimum standard. Bacterial endotoxin testing (LAL test) is also required for any injectable peptide.

Monitoring During the Stack

Before starting this or any peptide protocol, baseline labs provide a safety anchor. The HealthRX medical team recommends the following minimum panel:

• Complete metabolic panel (CMP)
• Complete blood count (CBC)
• Serum copper and ceruloplasmin
• C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) as inflammatory markers
• For older males: PSA (prostate-specific antigen)

Repeat CMP and serum copper at the end of the 8-week cycle. If serum copper rises above the upper reference limit (approximately 1.40 mcg/mL for adults), discontinue GHK-Cu until levels normalize [11].